ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Return
4.95%
This Quarter Return
+4.42%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$231M
AUM Growth
-$37.1M
(-14%)
Cap. Flow
-$49.7M
Cap. Flow
% of AUM
-21.54%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
85
New
16
Increased
17
Reduced
31
Closed
20
Top Buys
| 1 |
Cigna
CI
|
$7.45M |
| 2 |
Merck
MRK
|
$5.18M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
$3.48M |
| 4 |
Baxter International
BAX
|
$3.46M |
| 5 |
IQVIA
IQV
|
$3.29M |
Top Sells
| 1 |
Boston Scientific
BSX
|
$10.3M |
| 2 |
Becton Dickinson
BDX
|
$7.7M |
| 3 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$7.18M |
| 4 |
UnitedHealth
UNH
|
$7M |
| 5 |
Johnson & Johnson
JNJ
|
$6.73M |
Sector Composition
| 1 | Healthcare | 93.59% |
| 2 | Financials | 2.32% |
| 3 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Puma Biotechnology
PBYI
$257M
| $2.41M | 1.05% |
40,788
+16,088
| +65% | +$952K |
|
|
27
Boston Scientific
BSX
$159B
| $2.38M | 1.03% |
72,841
-314,857
| -81% | -$10.3M |
|
28
Cooper Companies
COO
$13.5B
| $2.22M | 0.96% |
+37,768
| New | +$2.22M |
|
29
Centene
CNC
$14.1B
| $2.17M | 0.94% |
+35,222
| New | +$2.17M |
|
|
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $2.02M | 0.88% |
156,869
-8,300
| -5% | -$107K |
|
31
Sabra Healthcare REIT
SBRA
$4.58B
| $1.98M | 0.86% |
90,922
-194,297
| -68% | -$4.22M |
|
|
SYNH
32
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $1.84M | 0.8% |
39,198
-153,202
| -80% | -$7.18M |
|
33
Regeneron Pharmaceuticals
REGN
$60.1B
| $1.83M | 0.79% |
5,300
+3,100
| +141% | +$1.07M |
|
34
Agilent Technologies
A
$36.4B
| $1.82M | 0.79% |
29,411
+9,411
| +47% | +$582K |
|
|
ESRX
35
DELISTED
Express Scripts Holding Company
ESRX
| $1.8M | 0.78% |
23,290
-31,500
| -57% | -$2.43M |
|
|
WBA
36
DELISTED
Walgreens Boots Alliance
WBA
| $1.75M | 0.76% |
29,148
-91,075
| -76% | -$5.46M |
|
37
McKesson
MCK
$86B
| $1.71M | 0.74% |
12,779
+1,256
| +11% | +$168K |
|
38
Stryker
SYK
$151B
| $1.58M | 0.69% |
+9,360
| New | +$1.58M |
|
|
PRAH
39
DELISTED
PRA Health Sciences, Inc.
PRAH
| $1.41M | 0.61% |
+15,068
| New | +$1.41M |
|
|
CLVS
40
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.39M | 0.6% |
30,500
-2,600
| -8% | -$118K |
|
|
ARRY
41
DELISTED
Array Biopharma Inc
ARRY
| $1.37M | 0.59% |
81,416
+10,016
| +14% | +$168K |
|
42
Pfizer
PFE
$140B
| $1.24M | 0.54% |
+35,996
| New | +$1.24M |
|
43
Bausch Health
BHC
$2.67B
| $1.09M | 0.47% |
46,929
-38,271
| -45% | -$890K |
|
44
Ocular Therapeutix
OCUL
$2.21B
| $964K | 0.42% |
142,775
-35,686
| -20% | -$241K |
|
45
Fate Therapeutics
FATE
$112M
| $936K | 0.41% |
82,572
-72,772
| -47% | -$825K |
|
|
MNK
46
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $909K | 0.39% |
+48,725
| New | +$909K |
|
47
Sarepta Therapeutics
SRPT
$1.93B
| $887K | 0.38% |
+6,714
| New | +$887K |
|
48
Amicus Therapeutics
FOLD
$2.47B
| $851K | 0.37% |
54,504
-72,496
| -57% | -$1.13M |
|
|
NVRO
49
DELISTED
NEVRO CORP.
NVRO
| $806K | 0.35% |
10,096
-605
| -6% | -$48.3K |
|
|
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $786K | 0.34% |
20,803
-50,697
| -71% | -$1.92M |
|